Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-01
1998-11-17
Chambers, Jasemine C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 42, 514 769, 5142222, 424520, 435 79, 435 72, 436518, 436811, A61K 3100, A61K 3800
Patent
active
058376720
ABSTRACT:
Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.
REFERENCES:
patent: 4486530 (1984-12-01), David et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 5221607 (1993-06-01), Cordell et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5538845 (1996-07-01), Knops et al.
Allsop, et al., "Immunohistochemical evidence for the derivative of a peptide ligand from the amyloid Beta protein precursor of Alzheimer disease", Proc. Natl. Acad. Sci. USA, 85:2790-2794, Apr. 1988.
Anderson, J.P., et al., "Exact cleavage site of Alzheimer amyloid presursor in neuronal PC-12 cells", Neuroscience Letters, 128:126-128, 1991.
Barrow and Zagorski, Science, 253:179, 1991.
Boller, et al., "Biological Markers of Alzheimer's Disease", Springer-Verlag (Berlin), pp. 24-29, 1989.
Bullock, et al., "Techniques in Diagnostic Pathology" vol. 2, Academic Press (London), pp. 100-112, 1991.
Burdick, et al., J. Biol. Chem., 267:546, 1992.
Castano, et al., "In Vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease Beta protein", Biochem. Biophys. Res. Comm., 141(2):782-789, Dec. 15, 1986.
Citron, M., et al., "Mutation of the Beta-amyloid precursor protein in familial Alzheimer's disease increases Beta-protein production", nature, 360:672-674.
Esch, et al., "Cleavage of amyloid Beta-peptide during constitutive processing of its precursor", Science, 248:1122-1124, Jun. 1, 1990.
Glenner and Wong, Biochem. Biophys. Res. Comm., 120:885, 1984.
Glenner and Wong, Biochem. Biophys. Res. Comm., 122:1131, 1984.
Haass, et al., "Amyloid Beta-peptide is produced by cultured cells during normal metabolism", Nature, vol. 359 pp. 322-325, Sep. 24, 1992.
Harlow and Lane, "Antibodies A Laboratory Manual", Cold Spring Harbor Laboratory, pp. 578-582, 1988.
Henriksson, et al., J. Neurochem., 56:1037, 1991.
Hilbich, et al., J. Mol. Biol., 218:149, 1991.
Joachim, et al., Brain Res., 474:100, 1988.
Joachim, et al., Nature, 341:226, 1989.
Kim and Wisniewski, "Techniques in diagnostic pathology", ed. Bullock et al., Academic Press-Boston, p. 106.
Kirschner, et al., "Synthetic peptide homologous to Beta-protein from Alzheimer disease forms amyloid-like fibrils in vito", Proc. Natl. Acad. Sci. USA, 84:6953-6957, Oct. 1987.
Ksiezak-Reder, et al., J. Biol. Chem., 263:7943-7947, 1988.
Lee, et al., Science, 251:675-678, 1991.
Masters, et al., Proc. Natl. Acad. Sci. USA, 82:4245, 1985.
McKhann, et al., "Clinical diagnosis of Alzheimer's disease", Neurology, 34:939-944, Jul. 1984.
Palmert, et al., Proc. Natl. Acad. Sci. USA, 86:6338, 1989.
Palmert, et al., Neurology, 40:1028, 1990.
Pardridge, et al., Biochem. Biophys. Res, Commun., 145:241, 1987.
Pennisi, et al., "A molecular whodunit", Science News, vol. 145 No. 1, pp. 8-11, Jan. 1, 1994.
Podlisny, et al., Biochem. Biophys. Res. Comm., 167:1094, 1990.
Rumble, et al., New Eng. J. of Med., 320:1446, 1989.
Schlossmacher, et al., Neurobiol. Aging, 13:421, 1992.
Selkoe, et al., J. Neurochem., 46:1820, 1986.
Selkoe, et al., Neurobiol. Aging, 7:425, 1986.
Selkoe, et al., Neurobiol. Aging, 10:387, 1989.
Seubert, et al., "Isolation and quantification of soluble Alzheimer's Beta-peptide from biological fluids", Nature, vol. 359 pp. 325-327, Sep. 24, 1992.
Seubert, et al., "Secretion of Beta-amyloid precursor protein cleaved at the amino terminus of the Beta-amyloid peptide", Nature, 361:260-263, 1993.
Ueda, et al., J. Neuroscience, 10:3295-3304, 1990.
Weidemann, et al., Cell, 57:115, 1989.
Wisniewski, "Alzheimer's disease", ed. Becker et al., p. 206.
Wolozin, et al., Science, 232:648-650, 1986.
Wong, et al., Proc. Natl. Acad. Sci. USA, 92:8729, 1985.
Price et al., "Cellular and Molecular Biology of Alzheimer's Disease and Animal Models," Annual Reviews, vol. 45: 435-446, 1994.
Prayson et al. "The search for diagnostic criteria in Alzheimer's disease: an update," Cleveland Clinic Journal of Medicine, vol. 61: 115-122, Apr. 1994.
Schenk Dale B.
Schlossmacher Michael G.
Selkoe Dennis J.
Seubert Peter A.
Vigo-Pelfrey Carmen
Athena Neurosciences, Inc.
Brigham and Women's Hospital
Chambers Jasemine C.
Eli Lilly and Company
Hauda Karen M.
LandOfFree
Methods and compositions for the detection of soluble .beta.-amy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the detection of soluble .beta.-amy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the detection of soluble .beta.-amy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-884449